In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
about
sameAs
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in miceEffects of the Chinese traditional medicine mao-bushi-saishin-to on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in miceMechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbitsIn vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859aIn vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilliActivity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine modelActivities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophagesIn vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivativesComparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacinIn vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric methodIn vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosisAntimycobacterial activity of a new rifamycin derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV (T9)Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine modelIn vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosisActivity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige miceAnticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cellsHow effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?Development potential of rifalazil.Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in miceFighting tuberculosis: an old disease with new challenges.Infection caused by Mycobacterium tuberculosis.In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs.Identification of enzymes responsible for rifalazil metabolism in human liver microsomes.Homology modeling of wild-type, D516V, and H526L Mycobacterium tuberculosis RNA polymerase and their molecular docking study with inhibitors.
P2860
Q28320238-CE3ACD12-A8F0-4FEE-933F-BA08168581A3Q28343163-ED970717-0394-4975-B38E-8F75C4C3E481Q28367444-520AFDFB-FFC9-4E65-91E3-8DFA975ED89AQ28368020-327E412E-B9C5-414D-844C-4251B9FA5B6CQ28368060-8FC173F3-2585-467D-8EA9-988357BF2948Q28368095-A23E91D7-BEFE-4265-B876-AFCAB98A8C32Q28368360-53B10F8A-663F-4DD9-A771-8986BB5626F8Q28369151-C5463EE5-DD9C-48C3-B0A0-5BFFD1043986Q28369383-4561889E-4188-4F93-BD31-6B004038023EQ28378625-FDD831FF-1F5F-428A-91A9-83FAA78B5EB7Q28378656-321B43F4-83D1-4ED6-86C3-22DC87EAA776Q28378826-69B248D2-FF12-4F8D-BC77-99EFAAE9B087Q28378827-3596691B-8679-4AEB-A470-64D3C6BD381CQ28379169-D906D467-2C90-4B20-9236-E44260437EFAQ28379172-F9C00CC3-FAE2-4533-AAB8-5A8126510CE6Q28379176-144307F5-0FD4-4856-917B-2A23CDFE3D03Q28379178-9A521827-AF04-4AB0-80F1-4692B7A7E41CQ28379180-B3A4CFAA-F829-4E2E-B6FE-ABC9017668FEQ35056073-B0F9B621-4EA7-462C-9EDA-192B16082F7BQ35122437-DB6C6181-F8E2-4946-9AE0-49B640524201Q35132348-6482EC96-4C77-4CF0-BC92-ED8CF0FDEB55Q35897225-8AE7A731-5776-4D74-BEC8-ADA876E9236AQ38569137-8E248F98-D9E1-4780-B647-C20B4A4BD49AQ39470015-1DD1FB39-48FD-42CB-B126-1E3DCFB7F506Q39783255-E64A622F-C37D-4FEA-99BD-9ACDF566E358Q43505733-F61FC6D9-2746-4B06-B1F5-0EE4BD8745A8Q46841769-3FFDD385-B9A5-48AA-8FF7-8DAE6E15FAE6
P2860
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
description
1991 nî lūn-bûn
@nan
1991 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի մարտին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@ast
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@en
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@nl
type
label
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@ast
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@en
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@nl
prefLabel
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@ast
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@en
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@nl
P2093
P2860
P356
P1476
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
@en
P2093
K Yamashita
P2860
P356
10.1128/AAC.35.3.542
P407
P577
1991-03-01T00:00:00Z